Monteris Medical raises $28 million to expand minimally invasive neurosurgery solutions

Medical technology company Monteris Medical has secured $28 million in series e equity financing to strengthen its position in the field of minimally invasive neurosurgery. The Minnesota-based firm plans to use the investment to expand its technology platform, support clinical development, and increase adoption of its surgical systems in hospitals. Company officials said the funding will help accelerate both innovation and revenue growth as demand for less invasive neurological procedures continues to rise, according to PR Newswire.

Series E focuses on technology development and clinical expansion

A significant portion of the newly raised funds will be used to advance Monteris Medical’s product development efforts. The company aims to refine and expand its surgical technologies to address a wider range of neurological conditions. Executives say strengthening research and engineering capabilities will allow the company to improve treatment precision and expand potential clinical uses.

At the center of Monteris’ portfolio is the NeuroBlate system, which uses laser interstitial thermal therapy (LITT) to treat certain brain disorders. The technology delivers laser energy through a small probe inserted into the brain, allowing surgeons to destroy abnormal tissue while limiting damage to surrounding areas. The system is used alongside magnetic resonance imaging (MRI), enabling physicians to monitor the procedure in real time and adjust treatment as needed.

This minimally invasive technique differs from traditional brain surgery, which typically requires opening the skull to access affected areas. By using a small entry point and targeted laser energy, the procedure can reduce the physical impact on patients. Surgeons may be able to complete treatments with shorter operating times and fewer complications compared with conventional surgical approaches.

Monteris Medical says the new investment will also help expand clinical research programs. Generating additional clinical evidence is essential for encouraging wider use of new surgical technologies, as hospitals and physicians often rely on study results when deciding whether to adopt innovative treatment methods. Increased research activity may help demonstrate the effectiveness of minimally invasive procedures for a broader range of neurological conditions.

Alongside research initiatives, the company intends to strengthen its commercial infrastructure. This includes expanding training programs for neurosurgeons and increasing the number of hospitals equipped with its surgical systems. By doing so, Monteris hopes to make its technology more accessible to physicians and patients.

Growing interest in clinical innovation

The funding reflects a broader trend within neurosurgery toward techniques that minimize surgical trauma. Traditional brain surgery can involve large incisions and lengthy recovery periods, which may limit treatment options for some patients. In contrast, minimally invasive approaches aim to deliver targeted therapy while preserving healthy brain tissue.

Laser-based therapies have gained attention in recent years as imaging technology and surgical tools have become more advanced. MRI-guided procedures allow surgeons to visualize the treatment area during the operation and monitor tissue temperature as the laser energy is applied. This level of control can help ensure that only the intended area is treated.

Such technologies are used in procedures addressing conditions including brain tumors, drug-resistant epilepsy, and radiation-related tissue damage. For certain patients who are not suitable candidates for conventional surgery, minimally invasive options may provide an alternative path to treatment.

Healthcare systems are also evaluating how these procedures can influence overall care efficiency. Shorter hospital stays and reduced recovery times may improve patient experiences while potentially lowering costs associated with long hospitalizations or postoperative complications.

Background on Monteris Medical

Monteris Medical is a privately held company focused on developing MRI-guided technologies designed specifically for neurosurgical procedures. The firm has spent years refining systems that combine imaging, robotics, and laser energy to treat abnormalities in the brain with high precision.

Its NeuroBlate platform has been introduced in hospitals across North America and has been used in thousands of neurosurgical procedures. Through ongoing clinical research and collaboration with medical institutions, the company continues to explore additional applications for its technology.

The broader medical device industry has shown increasing interest in technologies that integrate imaging and robotics with surgical tools. These developments are part of a wider effort to improve surgical accuracy and reduce the risks associated with complex procedures.

The $28 million financing round provides Monteris Medical with additional resources to expand its role in the evolving field of minimally invasive neurosurgery. By investing in product development, clinical studies, and physician training, the company aims to increase the availability of its laser-based surgical technology.

As hospitals continue to adopt treatments that prioritize precision and patient recovery, minimally invasive techniques are expected to play a growing role in neurological care. Monteris Medical’s latest funding round highlights the ongoing interest from investors and healthcare providers in technologies that could transform how certain brain disorders are treated.